Assertio Total Revenue vs Operating Income Analysis

ASRT Stock  USD 0.96  0.03  3.23%   
Assertio Therapeutics financial indicator trend analysis is way more than just evaluating Assertio Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Assertio Therapeutics is a good investment. Please check the relationship between Assertio Therapeutics Total Revenue and its Operating Income accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assertio Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Assertio Stock please use our How to Invest in Assertio Therapeutics guide.

Total Revenue vs Operating Income

Total Revenue vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Assertio Therapeutics Total Revenue account and Operating Income. At this time, the significance of the direction appears to have weak relationship.
The correlation between Assertio Therapeutics' Total Revenue and Operating Income is 0.33. Overlapping area represents the amount of variation of Total Revenue that can explain the historical movement of Operating Income in the same time period over historical financial statements of Assertio Therapeutics, assuming nothing else is changed. The correlation between historical values of Assertio Therapeutics' Total Revenue and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Revenue of Assertio Therapeutics are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Total Revenue i.e., Assertio Therapeutics' Total Revenue and Operating Income go up and down completely randomly.

Correlation Coefficient

0.33
Relationship DirectionPositive 
Relationship StrengthVery Weak

Total Revenue

Total revenue comprises all receipts Assertio Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Operating Income

Operating Income is the amount of profit realized from Assertio Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Assertio Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.
Most indicators from Assertio Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Assertio Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assertio Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Assertio Stock please use our How to Invest in Assertio Therapeutics guide.At this time, Assertio Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 81.8 M in 2024, despite the fact that Enterprise Value Over EBITDA is likely to grow to (0.19).
 2021 2022 2023 2024 (projected)
Gross Profit95.2M137.5M125.0M112.5M
Total Revenue111.0M156.2M152.1M128.0M

Assertio Therapeutics fundamental ratios Correlations

0.91-0.730.790.750.880.730.30.60.940.210.83-0.250.280.980.60.850.440.420.98-0.290.480.55-0.130.960.87
0.91-0.920.710.590.870.790.420.670.910.30.77-0.40.070.910.40.930.260.250.93-0.430.650.63-0.190.950.86
-0.73-0.92-0.5-0.49-0.68-0.67-0.43-0.8-0.75-0.3-0.620.340.11-0.74-0.29-0.93-0.18-0.18-0.760.42-0.75-0.540.18-0.82-0.68
0.790.71-0.50.310.650.77-0.10.340.850.420.88-0.10.260.850.20.550.040.00.79-0.040.10.320.070.770.65
0.750.59-0.490.310.610.220.390.570.52-0.170.54-0.060.170.60.860.710.760.760.65-0.220.620.5-0.130.630.57
0.880.87-0.680.650.610.640.460.450.820.110.64-0.450.210.880.540.760.420.40.91-0.520.480.69-0.190.850.99
0.730.79-0.670.770.220.640.050.380.910.680.73-0.230.350.82-0.080.59-0.25-0.270.8-0.090.130.2-0.160.860.65
0.30.42-0.43-0.10.390.460.050.290.17-0.38-0.07-0.85-0.370.250.440.470.490.510.37-0.930.640.66-0.150.320.5
0.60.67-0.80.340.570.450.380.290.540.250.42-0.14-0.020.560.420.770.360.360.58-0.220.720.37-0.020.620.45
0.940.91-0.750.850.520.820.910.170.540.470.84-0.220.330.970.280.760.110.080.96-0.190.320.4-0.110.960.82
0.210.3-0.30.42-0.170.110.68-0.380.250.470.310.130.580.3-0.510.14-0.62-0.650.260.39-0.19-0.420.080.330.13
0.830.77-0.620.880.540.640.73-0.070.420.840.310.050.220.830.340.710.150.110.79-0.010.270.370.010.830.63
-0.25-0.40.34-0.1-0.06-0.45-0.23-0.85-0.14-0.220.130.050.26-0.28-0.18-0.34-0.21-0.22-0.370.89-0.4-0.530.03-0.33-0.52
0.280.070.110.260.170.210.35-0.37-0.020.330.580.220.260.290.01-0.01-0.1-0.130.260.5-0.34-0.430.170.230.21
0.980.91-0.740.850.60.880.820.250.560.970.30.83-0.280.290.460.810.310.280.99-0.280.390.51-0.120.970.87
0.60.4-0.290.20.860.54-0.080.440.420.28-0.510.34-0.180.010.460.570.970.970.51-0.350.590.59-0.110.430.51
0.850.93-0.930.550.710.760.590.470.770.760.140.71-0.34-0.010.810.570.460.450.84-0.420.790.59-0.160.870.75
0.440.26-0.180.040.760.42-0.250.490.360.11-0.620.15-0.21-0.10.310.970.460.990.36-0.40.550.55-0.10.280.4
0.420.25-0.180.00.760.4-0.270.510.360.08-0.650.11-0.22-0.130.280.970.450.990.33-0.40.590.57-0.120.250.37
0.980.93-0.760.790.650.910.80.370.580.960.260.79-0.370.260.990.510.840.360.33-0.370.450.55-0.140.970.9
-0.29-0.430.42-0.04-0.22-0.52-0.09-0.93-0.22-0.190.39-0.010.890.5-0.28-0.35-0.42-0.4-0.4-0.37-0.56-0.770.12-0.32-0.57
0.480.65-0.750.10.620.480.130.640.720.32-0.190.27-0.4-0.340.390.590.790.550.590.45-0.560.72-0.170.480.47
0.550.63-0.540.320.50.690.20.660.370.4-0.420.37-0.53-0.430.510.590.590.550.570.55-0.770.72-0.220.520.68
-0.13-0.190.180.07-0.13-0.19-0.16-0.15-0.02-0.110.080.010.030.17-0.12-0.11-0.16-0.1-0.12-0.140.12-0.17-0.22-0.2-0.08
0.960.95-0.820.770.630.850.860.320.620.960.330.83-0.330.230.970.430.870.280.250.97-0.320.480.52-0.20.85
0.870.86-0.680.650.570.990.650.50.450.820.130.63-0.520.210.870.510.750.40.370.9-0.570.470.68-0.080.85
Click cells to compare fundamentals

Assertio Therapeutics Account Relationship Matchups

Assertio Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets527.2M303.3M326.5M413.9M286.4M336.5M
Short Long Term Debt Total351.3M84.1M73.5M66.9M40.9M38.9M
Other Current Liab2.1M103.3M114.2M88.5M79.1M83.0M
Total Current Liabilities184.6M132.7M135.0M95.3M93.4M72.3M
Total Stockholder Equity58.0M55.5M102.4M225.7M138.0M93.7M
Property Plant And Equipment Net3.5M2.4M1.5M744K2.0M1.9M
Net Debt309.2M63.3M36.7M1.9M(32.5M)(30.9M)
Retained Earnings(399.8M)(427.9M)(429.2M)(319.6M)(651.5M)(619.0M)
Accounts Payable16.2M14.8M6.7M6.0M13.4M15.6M
Non Current Assets Total423.2M209.0M223.0M281.7M115.4M203.4M
Non Currrent Assets Other6.1M4.9M5.5M2.4M2.0M2.1M
Net Receivables42.7M44.4M44.4M45.4M47.7M26.3M
Common Stock Shares Outstanding17.7M26.2M43.2M54.7M71.0M74.6M
Liabilities And Stockholders Equity527.2M303.3M326.5M413.9M286.4M336.5M
Other Current Assets15.7M34.8M29.7M16.5M24.2M25.5M
Total Liab469.2M247.8M224.1M188.2M148.4M242.8M
Total Current Assets104.0M94.3M103.5M132.3M171.1M133.1M
Short Term Debt80M14.6M14.2M871K928K881.6K
Cash42.1M20.8M36.8M64.9M73.4M80.2M
Cash And Short Term Investments42.1M20.8M36.8M64.9M73.4M95.5M
Non Current Liabilities Total284.7M115.1M89.1M92.9M55.0M52.2M
Other Stockholder Equity457.8M483.4M531.6M545.3M789.5M829.0M
Common Stock8K13K4K5K9K8.6K
Other Assets3.3M206.6M5.5M82.5M1.00.95
Long Term Debt271.3M72.2M61.3M66.4M38.2M36.3M
Property Plant Equipment3.5M4.8M1.5M881K1.0M962.5K
Current Deferred Revenue(2.4M)86.3M96.5M67.4M77.5M42.0M
Common Stock Total Equity313.9M6K8K13K11.7K11.1K
Property Plant And Equipment Gross3.5M2.4M1.5M744K6.7M5.7M
Other Liab8.6M40.1M27.8M26.5M23.8M29.7M
Inventory3.4M11.7M7.5M13.7M37.7M39.6M
Net Tangible Assets(342.6M)(144.6M)(113.6M)27.7M25.0M26.2M
Non Current Liabilities Other13.4M42.9M27.8M26.5M9.2M8.8M
Intangible Assets400.5M200.1M216.1M198.0M111.3M105.8M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Assertio Stock Analysis

When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.